retatrutide triple agonist glp-1 gip glucagon receptors receptor The data just dropped — and is rewriting what's possible in obesity medicine. 🧬 TRIUMPH-1 just released Phase 3 retatrutide triple agonist glp-1 gip

Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected

**Zdroje: Thondre PS, Lightowler H, Ahlstrom L, Gallagher A

Anskan Frukost och brunch vrd Gillar du tidiga morgnar, doften av nybakat och att skapa en skn start p dagen fr andra

Science 375 , eabm9609 (2022)

The medication triggers insulin production and reduces blood sugar levels, helping you reduce cravings and feel full longer with smaller food portions